Silicon Laboratories Inc.

Condensed Consolidated Statements of Cash Flows 

(In thousands) 

(Unaudited)

Three Months Ended

March 30,
2024

April 1,
2023

Operating Activities

Net income (loss)

$            (56,526)

$             13,967

Adjustments to reconcile net income to net cash used in operating activities:

Depreciation of property and equipment

6,634

6,235

Amortization of other intangible assets

6,079

6,510

Amortization of debt issuance costs

—

523

Loss on extinguishment of convertible debt

—

—

Stock-based compensation expense

13,612

16,638

Equity-method loss

—

1,033

Deferred income taxes

(5,270)

(2,670)

Changes in operating assets and liabilities:

Accounts receivable

(3,321)

(16,257)

Inventories

(3,958)

(32,794)

Prepaid expenses and other assets

(15,466)

11,530

Accounts payable

(13,829)

(12,966)

Other current liabilities and income taxes

1,554

(8,529)

Deferred revenue and returns liability

1,804

4,478

Other non-current liabilities

(3,113)

(978)

Net cash used in operating activities

(71,800)

(13,280)

Investing Activities

Purchases of marketable securities

(9,794)

(66,113)

Sales of marketable securities

25,763

170,317

Maturities of marketable securities

55,188

157,734

Purchases of property and equipment

(2,047)

(7,657)

Proceeds from sale of equity investment

12,382

—

Net cash provided by investing activities

81,492

254,281

Financing Activities

Payments on debt

(45,000)

—

Repurchases of common stock

—

(17,608)

Payment of taxes withheld for vested stock awards

(1,048)

(6,931)

Proceeds from the issuance of common stock

341

—

Net cash used in financing activities

(45,707)

(24,539)

Increase (decrease) in cash and cash equivalents

(36,015)

216,462

Cash and cash equivalents at beginning of period

227,504

499,915

Cash and cash equivalents at end of period

$           191,489

$           716,377